Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: OSI Pharmaceuticals
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
Evaluate in parallel the efficacy of 2 different Tarceva-containing regimens as first-line therapy measured as the percentage of patients that have progressed at 6 months among stage IIIB/IV NSCLC pat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
To determine the objective response rates in patients with untreated unresectable, locally advanced or metastatic cancer of the biliary tract who are treated with OSI-7904L or 5-FU/LV.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
OSI Pharmaceuticals
Update Il y a 4 ans
OSI Pharmaceuticals RADIANT : Essai de phase 3 randomisé, en double aveugle évaluant l’efficacité de l’erlotinib (Tarceva®) suivi d’une résection tumorale complète, avec ou sans chimiothérapie, chez des patients ayant un carcinome du poumon non à petites cellules de stade IB-IIIA et présentant le récepteur à l’EGF (EGF-R). [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité d’un traitement par l’erlotinib (Tarceva®) suivi d’une résection complète de la tumeur chez des patients ayant un cancer du poumon non à petites cell...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
OSI Pharmaceuticals
Update Il y a 4 ans
OSI-906-301 : Essai de phase 3 randomisé, en double aveugle, comparant l'efficacité d'un inhibiteur de l'IGF-1R (OSI-906) à un placebo, chez des patients ayant un carcinome adrénocortical, localement avancé ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized, double-blind, placebo-controlled, phase 3 study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma.
Country
France
organs
Système endocrinien - autres
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors. Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo
The primary objectives of this study are to assess the efficacy of single agent, oral, once daily, Tarceva (150 mg/day) at increasing the DFS following complete surgical resection with or without adju...
Country
None
organs
None
Specialty
None
Closed trial
More information